Expanded North Carolina Crown Bioscience recently expanded facilities to Kannapolis, North Carolina, signaling a strategic push to strengthen East Coast PDX services and reduce client timelines for American-based projects.

PDX and Organoid Lead Boasts the world’s largest commercially available patient-derived xenograft collection and extensive tumor organoid models, presenting a strong value proposition for partners seeking robust preclinical oncology platforms and translational insights.

Strategic Partnerships Active collaborations with Turbine for AI-driven predictions and recent radiochemistry/imaging integration with Catapult indicate a readiness to offer integrated, advanced analytics and imaging solutions to accelerate translational research.

Awarded Excellence Recognized as Best Preclinical Oncology CRO in 2025, reinforcing credibility with potential clients and supporting pitches around quality, reliability, and outcomes in oncology programs.

End-to-End Capabilities Comprehensive in vivo, in vitro, ex vivo, and in silico services plus a large biobank enable one-stop preclinical support across 35 cancer indications, appealing to sponsors seeking speed, breadth, and integrated data for oncology asset testing.